CGEMCullinan Oncology, Inc.

Nasdaq cullinanoncology.com


$ 18.25 $ 0.27 (1.5 %)    

Monday, 09-Sep-2024 15:59:56 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 18.25
$ 18.27
$ 18.23 x 100
$ 18.27 x 100
$ 18.00 - $ 18.42
$ 7.64 - $ 30.19
549,154
na
1.06B
$ 0.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-14-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-09-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-17-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-10-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mercks-13b-deal-for-potential-autoimmune-disorder-candidate-is-relevant-to-cullinans-investigational-drug-says-analyst

Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims ...

 wedbush-reiterates-outperform-on-cullinan-therapeutics-maintains-36-price-target

Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $36 price tar...

 hc-wainwright--co-reiterates-buy-on-cullinan-therapeutics-maintains-28-price-target

HC Wainwright & Co. analyst Edward White reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $28 pri...

 reported-saturday-cullinan-therapeutics-announced-initial-data-from-pivotal-phase-2b-rezilient1-study-of-zipalertinib

As of a January 12, 2024 data cut-off, 31 patients had been enrolled. Patients had received a median of three prior systemic an...

 hc-wainwright--co-reiterates-buy-on-cullinan-therapeutics-maintains-28-price-target

HC Wainwright & Co. analyst Edward White reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $28 pri...

 cullinan-therapeutics-files-for-resale-of-up-to-144m-shares-by-the-selling-stockholders

- SEC Filing

 hc-wainwright--co-maintains-buy-on-cullinan-therapeutics-lowers-price-target-to-28

HC Wainwright & Co. analyst Edward White maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and lowers the price t...

 wedbush-reiterates-outperform-on-cullinan-therapeutics-maintains-36-price-target

Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $36 price tar...

 stifel-initiates-coverage-on-cullinan-therapeutics-with-buy-rating-announces-price-target-of-40

Stifel analyst Bradley Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Pric...

 why-is-cullinan-therapeutics-stock-trading-higher-on-wednesday

Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN...

 cullinan-therapeutics-to-present-clinical-data-from-phase-1-study-evaluating-novel-anti-micab-antibody-cln-619-as-monotherapy-and-in-combination-with-a-checkpoint-inhibitor-in-patients-with-advanced-solid-tumors-at-asco-2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today a...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION